MedTrace Logo

Yale COVID-19 Recovery Study

NCT04895189 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2025-05-29

No results posted yet for this study

Summary

The general purpose of the study is to determine the change in immune responses in people with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) after vaccination. PASC is a disabling, heterogeneous condition in which people have persistent or emerging symptoms months after an initial SARS-CoV-2 infection, (the virus that causes coronavirus disease 2019, or COVID-19. Specifically, the purpose is to enroll participants suffering from moderate-to-severe PASC prior to vaccination and to measure participants' immune and symptom profiles both before and after vaccination. This study is primarily descriptive.

Conditions

  • Covid19 Sequelae

Interventions

OTHER

No intervention

There is no intervention for this observational study. The investigators are observing the changes in participants before and after the participants receive the COVID-19 vaccine, which participants will receive outside of the study.

Sponsors & Collaborators

  • Food and Drug Administration (FDA)

    collaborator FED

  • Yale University

    lead OTHER

Principal Investigators

  • Harlan Krumholz, MD, SM · Director, Center for Outcomes Research and Evaluation (CORE)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-03
Primary Completion
2023-06-09
Completion
2025-05-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04895189 on ClinicalTrials.gov